BIRC5 and diffuse large B-cell lymphoma: Survivin showed significant immunoexpression at initial diagnosis either in Remission (39.4% ± 11.3), Relapsed (52.0% ± 13.9, p < 0.05 vs. Remission), or Refractory DLBCL cell (74.6% ± 15.3, p < 0.001 vs. Remission, p = 0.33 vs. Relapsed) groups (Figure 4).